The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice

Vascular Pharmacology

Volumn 76, Issue , 2015, Pages 28-36

  Husarek, Kathryn E ^a,b   Katz, Paige S ^a,c   Trask, Aaron J ^a,b   Galantowicz, Maarten L ^a   Cismowski, Mary J ^a   Lucchesi, Pamela A ^a,b  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin receptor blocker; Coronary arterioles; Type 2 diabetes mellitus; Vascular remodeling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CANDESARTAN HEXETIL; COLLAGEN TYPE 1; ELASTIN; GLUCOSE; INSULIN; LOSARTAN; MESSENGER RNA; RNA; ANGIOTENSIN RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL DIAMETER; BLOOD VESSEL PARAMETERS; BODY WEIGHT; CAPILLARY DENSITY; CELL COUNT; CONTROLLED STUDY; CORONARY ARTERIOLE REMODELING; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE DELETION; GLUCOSE BLOOD LEVEL; HEART HYPERTROPHY; HEART RATE; HYPEREMIA; INSULIN BLOOD LEVEL; MALE; MOUSE; MUSCLE GROWTH; MYOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RNA ANALYSIS; STRESS STRAIN RELATIONSHIP; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; WALL STRESS; WALL TO LUMEN RATIO; YOUNG MODULUS; ANIMAL; ARTERIOLE; BLOOD PRESSURE; CORONARY BLOOD VESSEL; DIABETES MELLITUS, TYPE 2; DIET THERAPY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HYPERTENSION; METABOLISM; MICROVASCULATURE; PILOT STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; ARTERIOLES; BLOOD PRESSURE; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; HYPERTENSION; LOSARTAN; MALE; MICE; MICROVESSELS; MUSCLE, SMOOTH, VASCULAR; PILOT PROJECTS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 84961136217     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.06.013     Document Type: Article

References (52)

1. F. Amiri, S. Shaw, X.Wang, J. Tang, J.L.Waller, D.C. Eaton, M.B. Marrero, Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose, Kidney Int. 61 (2002) 1605-1616
2. S. Anderson, Role of local and systemic angiotensin in diabetic renal disease, Kidney Int. Suppl. 63 (1997) S107-S110
3. S.L. Archer, Diversity of phenotype and function of vascular smooth muscle cells, J. Lab. Clin. Med. 127 (1996) 524-529
4. J.N. Cohn, G. Tognoni, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N. Engl. J. Med. 345 (2001) 1667-1675
5. P. Deedwania, S. Srikanth, Diabetes and vascular disease, Expert. Rev. Cardiovasc. Ther. 6 (2008) 127-138
6. D.X. Deng, A. Tsalenko, A. Vailaya, A. Ben-Dor, R. Kundu, I. Estay, R. Tabibiazar, R. Kincaid, Z. Yakhini, L. Bruhn, T. Quertermous, Differences in vascular bed disease susceptibility reflect differences in gene expression response to atherogenic stimuli, Circ. Res. 98 (2006) 200-208
7. D.J. Duncker, R.J. Bache, Regulation of coronary blood flow during exercise, Physiol. Rev. 88 (2008) 1009-1086
8. D.H. Endemann, Q. Pu, C. De Ciuceis, C. Savoia, A. Virdis, M.F. Neves, R.M. Touyz, E.L. Schiffrin, Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment, Hypertension 43 (2004) 399-404
9. S.A. Fisher, Vascular smooth muscle phenotypic diversity and function, Physiol. Genomics 42A (2010) 169-187
10. C. Fiuza-Luces, N. Garatachea, N.A. Berger, A. Lucia, Exercise is the real polypill, Physiology (Bethesda) 28 (2013) 330-358
11. X. Gao, X. He, B. Luo, L. Peng, J. Lin, Z. Zuo, Angiotensin II increases collagen I expression via transforming growth factor-beta1 and extracellular signal-regulated kinase in cardiac fibroblasts, Eur. J. Pharmacol. 606 (2009) 115-120
12. T. Hayashi, K. Sohmiya, A. Ukimura, S. Endoh, T. Mori, H. Shimomura, M. Okabe, F. Terasaki, Y. Kitaura, Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart, Heart 89 (2003) 1236-1242
13. Z. He, G.L. King, Microvascular complications of diabetes, Endocrinol. Metab. Clin. N. Am. 33 (215-238) (2004) xi-xii
14. S. Heeneman, J.C. Sluimer, M.J. Daemen, Angiotensin-converting enzyme and vascular remodeling, Circ. Res. 101 (2007) 441-454
15. T. Hinoi, Y. Tomohiro, S. Kajiwara, S.Matsuo, Y. Fujimoto, S. Yamamoto, T. Shichijo, T. Ono, Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy, Hypertens. Res. 31 (2008) 615-622
16. P. Hogan, T. Dall, P. Nikolov, Economic costs of diabetes in the US in 2002, Diabetes Care 26 (2003) 917-932
17. Investigators, H.O.P.E.S., Effects of ramipril on cardiovascular andmicrovascular outcomes in peoplewith diabetesmellitus: results of the HOPE study andMICRO-HOPE substudy, Lancet 355 (2000) 253-259
18. H.V. Joffe, R.Y. Kwong, M.D. Gerhard-Herman, C. Rice, K. Feldman, G.K. Adler, Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus, J. Clin. Endocrinol. Metab. 92 (2007) 2552-2558
19. P.S. Katz, A.J. Trask, F.M. Souza-Smith, K.R. Hutchinson, M.L. Galantowicz, K.C. Lord, J.A. Stewart Jr., M.J. Cismowski, K.J. Varner, P.A. Lucchesi, Coronary arterioles in type 2 diabetic (db/db) mice undergo a distinct pattern of remodeling associated with decreased vessel stiffness, Basic Res. Cardiol. 106 (2011) 1123-1134
20. T. Kawata,M. Daimon, R. Hasegawa, K. Teramoto, T. Toyoda, T. Sekine, K. Yamamoto, D. Uchida, T. Himi, K. Yoshida, I. Komuro, Effect on coronary flow velocity reserve in patients with type 2 diabetesmellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist, Am. Heart J. 151 (2006) (798 e799-715)
21. A. Kjaer, U.S. Kristoffersen, L. Tarnow, H.H. Parving, B. Hesse, Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients, Diabetes Res. Clin. Pract. 84 (2009) 34-38
22. A.J. Krentz, G. Clough, C.D. Byrne, Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications, Diabetes Obes. Metab. 9 (2007) 781-791
23. S.P. Laing, A.J. Swerdlow, S.D. Slater, A.C. Burden, A. Morris, N.R.Waugh,W. Gatling, P.J. Bingley, C.C. Patterson, Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes, Diabetologia 46 (2003) 760-765
24. C.A. Lemarie, E.L. Schiffrin, The angiotensin II type 2 receptor in cardiovascular disease, J. Renin-Angiotensin-Aldosterone Syst. 11 (2010) 19-31
25. L.H. Lindholm, H. Ibsen, B. Dahlof, R.B. Devereux, G. Beevers, U. de Faire, F. Fyhrquist, S. Julius, S.E. Kjeldsen, K. Kristiansson, O. Lederballe-Pedersen, M.S. Nieminen, P. Omvik, S. Oparil, H.Wedel, P. Aurup, J. Edelman, S. Snapinn, Cardiovascular morbidity andmortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet 359 (2002) 1004-1010
26. P. Marin, B. Andersson, M. Krotkiewski, P. Bjorntorp, Muscle fiber composition and capillary density in women and men with NIDDM, Diabetes Care 17 (1994) 382-386
27. M.B. Marrero, D. Fulton, D. Stepp, D.M. Stern, Angiotensin II-induced signaling pathways in diabetes, Curr. Diabetes Rev. 1 (2005) 197-202
28. M.B. Marrero, B. Schieffer, B. Li, J. Sun, J.B. Harp, B.N. Ling, Role of Janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation, J. Biol. Chem. 272 (1997) 24684-24690
29. S.P. Marso, D.M. Stern, Diabetes and Cardiovascular Disease: Integrating Science and Clinical Medicine, Lippincott Williams & Wilkins, Philadelphia, 2004
30. P.E. McEwan, G.A. Gray, L. Sherry, D.J. Webb, C.J. Kenyon, Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo, Circulation 98 (1998) 2765-2773
31. P.K. Mehta, K.K. Griendling, Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system, Am. J. Physiol. Cell Physiol. 292 (2007) C82-C97
32. H. Methe, M. Balcells, C. Alegret Mdel, M. Santacana, B. Molins, A. Hamik, M.K. Jain, E.R. Edelman, Vascular bed origin dictates flow pattern regulation of endothelial adhesion molecule expression, Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H2167-H2175
33. P.J. Nahser Jr., R.E. Brown, H. Oskarsson, M.D. Winniford, J.D. Rossen, Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus, Circulation 91 (1995) 635-640
34. R.A. Neese, L.M. Misell, S. Turner, A. Chu, J. Kim, D. Cesar, R. Hoh, F. Antelo, A. Strawford, J.M. McCune, M. Christiansen, M.K. Hellerstein, Measurement in vivo of proliferation rates of slowturnover cells by 2H2O labeling of the deoxyribosemoiety of DNA, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 15345-15350
35. A. Nitenberg, P. Valensi, R. Sachs, M. Dali, E. Aptecar, J.R. Attali, Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function, Diabetes 42 (1993) 1017-1025
36. S. Park, B.J. Bivona, L.M. Harrison-Bernard, Compromised renal microvascular reactivity of angiotensin type 1 double null mice, Am. J. Physiol. Ren. Physiol. 293 (2007) F60-F67
37. E. Ragni, M. Vigano, P. Rebulla, R. Giordano, L. Lazzari, What is beyond a qRT-PCR study on mesenchymal stem cell differentiation properties: how to choose the most reliable housekeeping genes, J. Cell. Mol. Med. 17 (2013) 168-180
38. E.L. Schiffrin, J.B. Park, H.D. Intengan, R.M. Touyz, Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan, Circulation 101 (2000) 1653-1659
39. I. Schofield, R. Malik, A. Izzard, C. Austin, A. Heagerty, Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia, Circulation 106 (2002) 3037-3043
40. H.M. Siragy, The role of the AT2 receptor in hypertension, Am. J. Hypertens. 13 (2000) 62S-67S
41. R.M. Touyz, E.L. Schiffrin, Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smoothmuscle cells, Pharmacol. Rev. 52 (2000) 639-672
42. A.J. Trask, M.A. Delbin, P.S. Katz, A. Zanesco, P.A. Lucchesi, Differential coronary resistance microvessel remodeling between type 1 and type 2 diabetic mice: impact of exercise training, Vasc. Pharmacol. 57 (2012) 187-193
43. A.J. Trask, P.S. Katz, A.P. Kelly,M.L. Galantowicz,M.J. Cismowski, T.A.West, Z.P. Neeb, Z.C. Berwick, A.G. Goodwill, M. Alloosh, J.D. Tune, M. Sturek, P.A. Lucchesi, Dynamic micro- and macrovascular remodeling in coronary circulation of obese Ossabaw pigs with metabolic syndrome, J. Appl. Physiol. (1985) 113 (2012) 1128-1140
44. J. Tunon, M. Ruiz-Ortega, J. Egido, Regulation of matrix proteins and impact on vascular structure, Curr. Hypertens. Rep. 2 (2000) 106-113
45. M. Vavuranakis, C. Stefanadis, E. Triandaphyllidi, K. Toutouzas, P. Toutouzas, Coronary artery distensibility in diabetic patients with simultaneous measurements of luminal area and intracoronary pressure: evidence of impaired reactivity to nitroglycerin, J. Am. Coll. Cardiol. 34 (1999) 1075-1081
46. M.R. Weir, Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin. Ther. 29 (2007) 1803-1824
47. G.Wolf, Growth factors and the development of diabetic nephropathy, Curr. Diabetes Rep. 3 (2003) 485-490
48. J. Yang, Y. Tan, F. Zhao, Z. Ma, Y.Wang, S. Zheng, P.N. Epstein, J. Yu, X. Yin, Y. Zheng, X. Li, L. Miao, L. Cai, Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of NADPH oxidase-mediated nitrosative damage, Am. J. Physiol. Endocrinol. Metab. 301 (2011) E132-E144
49. I. Yokoyama, S. Momomura, T. Ohtake, K. Yonekura, J. Nishikawa, Y. Sasaki, M. Omata, Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus, J. Am. Coll. Cardiol. 30 (1997) 1472-1477
50. C. Zhang, J.D. Knudson, S. Setty, A. Araiza, U.D. Dincer, L. Kuo, J.D. Tune, Coronary arteriolar vasoconstriction to angiotensin II is augmented in prediabetic metabolic syndrome via activation of AT1 receptors, Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H2154-H2162
51. H. Zhang, Y. Park, C. Zhang, Coronary and aortic endothelial function affected by feedback between adiponectin and tumor necrosis factor alpha in type 2 diabetic mice, Arterioscler. Thromb. Vasc. Biol. 30 (2010) 2156-2163
52. S. Zoneraich, Small-vessel disease, coronary artery vasodilator reserve, and diabetic cardiomyopathy, Chest 94 (1988) 5-7